glp-1 weight loss drug news today 2025 Alarming rise in overdoses New GLP-1 alternative, eloralintide, leads

Chou SH, Chamberland JP, Liu X, Matarese G, Gao C, Stefanakis R, et al

In follow-up from the STEP 1 trial on semaglutide, average weight loss on semaglutide was 17.3% at week 68

Foundayo is a small molecule that can be taken at any time of day without food or water restrictions

2023 Nov 3:1-8 Yang WL, Zhang CY, Ji WY, et al

The trial was double-blinded, meaning neither the investigators nor the persons with Parkinsons were made aware of who was actually receiving an active drug (rather than a placebo/inactive drug)

The Saxenda Spin-Off: Another Weight Management Star While Ozempic and Wegovy have garnered much attention, let's not forget another GLP-1 receptor agonist family member that's been turning heads in the weight management world for years now: Saxenda (liraglutide)